Aspirin and heparin in pregnancy

Research output: Contribution to journalArticle

Abstract

Introduction: A pro-coagulant state during pregnancy can be involved in the occurrence of gestational vascular complications (GVCs) and venous thromboembolism (VTE).Areas covered: Antithrombotic drugs are used to prevent GVCs and VTE. Aspirin is not efficacious to prevent recurrences in women with previous early loss, while it can prevent pre-eclampsia in some groups of women. Heparins are not effective in the prevention of early recurrent loss and there is uncertainty about their efficacy in women carrying inherited thrombophilias. They could be efficacious in the prevention of GVCs in carriers of inherited thrombophilias, as GVCs have heterogeneous causes, and future studies have to focus on more homogeneous groups of patients. Not enough data are available regarding prophylaxis with heparins to prevent pregnancy-related VTE, but an accurate risk stratification of women during pregnancy and puerperium is crucial for administering prophylaxis in moderate-/high-risk women. Aspirin does not improve live births after assisted reproductive technologies, while heparins increase the number of clinical pregnancies and live births.Expert opinion: Aspirin is efficacious in the prevention of GVCs in women at risk for pre-eclampsia and in those with antiphospholipid antibodies syndrome. Heparins could give benefit to women at risk for GVCs and/or pregnancy-related VTE.

Original languageEnglish
Pages (from-to)1793-1803
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number12
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Aspirin
Heparin
Blood Vessels
Venous Thromboembolism
Pregnancy
Live Birth
Pre-Eclampsia
Coagulants
Assisted Reproductive Techniques
Antiphospholipid Syndrome
Pregnancy Complications
Expert Testimony
Postpartum Period
Uncertainty
Recurrence
Pharmaceutical Preparations

Keywords

  • aspirin
  • gestational vascular complications
  • heparin
  • venous thromboembolism

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

Aspirin and heparin in pregnancy. / Grandone, Elvira; Villani, Michela; Tiscia, Giovanni L.

In: Expert Opinion on Pharmacotherapy, Vol. 16, No. 12, 01.08.2015, p. 1793-1803.

Research output: Contribution to journalArticle

@article{408a62eb71cd4c08ac8e5876a6039389,
title = "Aspirin and heparin in pregnancy",
abstract = "Introduction: A pro-coagulant state during pregnancy can be involved in the occurrence of gestational vascular complications (GVCs) and venous thromboembolism (VTE).Areas covered: Antithrombotic drugs are used to prevent GVCs and VTE. Aspirin is not efficacious to prevent recurrences in women with previous early loss, while it can prevent pre-eclampsia in some groups of women. Heparins are not effective in the prevention of early recurrent loss and there is uncertainty about their efficacy in women carrying inherited thrombophilias. They could be efficacious in the prevention of GVCs in carriers of inherited thrombophilias, as GVCs have heterogeneous causes, and future studies have to focus on more homogeneous groups of patients. Not enough data are available regarding prophylaxis with heparins to prevent pregnancy-related VTE, but an accurate risk stratification of women during pregnancy and puerperium is crucial for administering prophylaxis in moderate-/high-risk women. Aspirin does not improve live births after assisted reproductive technologies, while heparins increase the number of clinical pregnancies and live births.Expert opinion: Aspirin is efficacious in the prevention of GVCs in women at risk for pre-eclampsia and in those with antiphospholipid antibodies syndrome. Heparins could give benefit to women at risk for GVCs and/or pregnancy-related VTE.",
keywords = "aspirin, gestational vascular complications, heparin, venous thromboembolism",
author = "Elvira Grandone and Michela Villani and Tiscia, {Giovanni L.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1517/14656566.2015.1066335",
language = "English",
volume = "16",
pages = "1793--1803",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - Aspirin and heparin in pregnancy

AU - Grandone, Elvira

AU - Villani, Michela

AU - Tiscia, Giovanni L.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Introduction: A pro-coagulant state during pregnancy can be involved in the occurrence of gestational vascular complications (GVCs) and venous thromboembolism (VTE).Areas covered: Antithrombotic drugs are used to prevent GVCs and VTE. Aspirin is not efficacious to prevent recurrences in women with previous early loss, while it can prevent pre-eclampsia in some groups of women. Heparins are not effective in the prevention of early recurrent loss and there is uncertainty about their efficacy in women carrying inherited thrombophilias. They could be efficacious in the prevention of GVCs in carriers of inherited thrombophilias, as GVCs have heterogeneous causes, and future studies have to focus on more homogeneous groups of patients. Not enough data are available regarding prophylaxis with heparins to prevent pregnancy-related VTE, but an accurate risk stratification of women during pregnancy and puerperium is crucial for administering prophylaxis in moderate-/high-risk women. Aspirin does not improve live births after assisted reproductive technologies, while heparins increase the number of clinical pregnancies and live births.Expert opinion: Aspirin is efficacious in the prevention of GVCs in women at risk for pre-eclampsia and in those with antiphospholipid antibodies syndrome. Heparins could give benefit to women at risk for GVCs and/or pregnancy-related VTE.

AB - Introduction: A pro-coagulant state during pregnancy can be involved in the occurrence of gestational vascular complications (GVCs) and venous thromboembolism (VTE).Areas covered: Antithrombotic drugs are used to prevent GVCs and VTE. Aspirin is not efficacious to prevent recurrences in women with previous early loss, while it can prevent pre-eclampsia in some groups of women. Heparins are not effective in the prevention of early recurrent loss and there is uncertainty about their efficacy in women carrying inherited thrombophilias. They could be efficacious in the prevention of GVCs in carriers of inherited thrombophilias, as GVCs have heterogeneous causes, and future studies have to focus on more homogeneous groups of patients. Not enough data are available regarding prophylaxis with heparins to prevent pregnancy-related VTE, but an accurate risk stratification of women during pregnancy and puerperium is crucial for administering prophylaxis in moderate-/high-risk women. Aspirin does not improve live births after assisted reproductive technologies, while heparins increase the number of clinical pregnancies and live births.Expert opinion: Aspirin is efficacious in the prevention of GVCs in women at risk for pre-eclampsia and in those with antiphospholipid antibodies syndrome. Heparins could give benefit to women at risk for GVCs and/or pregnancy-related VTE.

KW - aspirin

KW - gestational vascular complications

KW - heparin

KW - venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84937688005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937688005&partnerID=8YFLogxK

U2 - 10.1517/14656566.2015.1066335

DO - 10.1517/14656566.2015.1066335

M3 - Article

C2 - 26155946

AN - SCOPUS:84937688005

VL - 16

SP - 1793

EP - 1803

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 12

ER -